Aug 14, 2026 08:00AM
Aug 4, 2026 08:04AM
Aug 4, 2026 08:00AM
Jun 23, 2026 08:00AM
Jun 23, 2026 08:00AM
May 27, 2026 08:00AM
May 15, 2026 08:00AM Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
May 11, 2026 08:00AM
May 11, 2026 08:00AM
Mar 31, 2026 08:00AM
Mar 17, 2026 08:01AM
Mar 17, 2026 08:00AM
Feb 26, 2026 04:05PM
Dec 19, 2025 08:01AM Galectin Therapeutics receives FDA feedback and secures $10M credit line
Dec 19, 2025 08:00AM
Nov 14, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 20, 2025 08:00AM
Oct 7, 2025 08:00AM
Sep 2, 2025 08:00AM Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 14, 2025 08:00AM
Jul 9, 2025 08:01AM
Jul 9, 2025 08:00AM
Jun 10, 2025 08:56AM
May 15, 2025 08:00AM
May 12, 2025 08:07AM
May 12, 2025 08:00AM Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Apr 15, 2025 08:00AM
Mar 31, 2025 08:00AM
Feb 18, 2025 08:06AM
Feb 18, 2025 08:00AM
Jan 10, 2025 08:00AM
Dec 27, 2024 12:32PM
Dec 20, 2024 08:01AM Galectin Therapeutics (GALT) Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
Dec 20, 2024 08:00AM
Nov 18, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 15, 2024 08:00AM
Sep 30, 2024 08:00AM
Sep 3, 2024 08:30AM
Aug 13, 2024 08:00AM Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Aug 1, 2024 08:02AM
Aug 1, 2024 08:00AM
Jun 4, 2024 08:00AM
May 15, 2024 08:00AM
May 13, 2024 08:00AM
Apr 9, 2024 08:01AM
Apr 9, 2024 08:00AM Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caus
Mar 29, 2024 08:00AM

330,211 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All